Chugai Pharmaceutical Co. vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chugai Pharmaceutical Co., Ltd. (4519.JP)

Q3 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

August 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Latest24 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.